GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (NAS:EXEL) » Definitions » Cyclically Adjusted PB Ratio

Exelixis (Exelixis) Cyclically Adjusted PB Ratio : 5.13 (As of May. 14, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Exelixis Cyclically Adjusted PB Ratio?

As of today (2024-05-14), Exelixis's current share price is $20.99. Exelixis's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $4.09. Exelixis's Cyclically Adjusted PB Ratio for today is 5.13.

The historical rank and industry rank for Exelixis's Cyclically Adjusted PB Ratio or its related term are showing as below:

EXEL' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 5.1   Med: 14.11   Max: 223
Current: 5.2

During the past years, Exelixis's highest Cyclically Adjusted PB Ratio was 223.00. The lowest was 5.10. And the median was 14.11.

EXEL's Cyclically Adjusted PB Ratio is ranked worse than
79.22% of 645 companies
in the Biotechnology industry
Industry Median: 1.79 vs EXEL: 5.20

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Exelixis's adjusted book value per share data for the three months ended in Mar. 2024 was $7.213. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.09 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Exelixis Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Exelixis's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Cyclically Adjusted PB Ratio Chart

Exelixis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.91 12.47 7.59 5.08 6.12

Exelixis Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.77 5.37 5.81 6.12 5.80

Competitive Comparison of Exelixis's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Exelixis's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exelixis's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exelixis's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Exelixis's Cyclically Adjusted PB Ratio falls into.



Exelixis Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Exelixis's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=20.99/4.09
=5.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exelixis's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Exelixis's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=7.213/129.4194*129.4194
=7.213

Current CPI (Mar. 2024) = 129.4194.

Exelixis Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.017 100.560 0.022
201409 -0.300 100.428 -0.387
201412 -0.586 99.070 -0.766
201503 -0.749 99.621 -0.973
201506 -0.958 100.684 -1.231
201509 -0.328 100.392 -0.423
201512 -0.618 99.792 -0.801
201603 -0.682 100.470 -0.879
201606 -0.808 101.688 -1.028
201609 0.112 101.861 0.142
201612 0.308 101.863 0.391
201703 0.410 102.862 0.516
201706 0.506 103.349 0.634
201709 0.807 104.136 1.003
201712 0.962 104.011 1.197
201803 2.257 105.290 2.774
201806 2.602 106.317 3.167
201809 3.065 106.507 3.724
201812 4.293 105.998 5.242
201903 4.593 107.251 5.542
201906 4.916 108.070 5.887
201909 5.279 108.329 6.307
201912 5.531 108.420 6.602
202003 5.715 108.902 6.792
202006 5.935 108.767 7.062
202009 5.986 109.815 7.055
202012 6.030 109.897 7.101
202103 6.101 111.754 7.065
202106 6.490 114.631 7.327
202109 6.679 115.734 7.469
202112 6.933 117.630 7.628
202203 7.162 121.301 7.641
202206 7.431 125.017 7.693
202209 7.724 125.227 7.983
202212 7.681 125.222 7.938
202303 7.862 127.348 7.990
202306 7.894 128.729 7.936
202309 7.549 129.860 7.523
202312 7.477 129.419 7.477
202403 7.213 129.419 7.213

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Exelixis  (NAS:EXEL) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Exelixis Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Exelixis's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Exelixis (Exelixis) Business Description

Industry
Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Executives
Patrick J. Haley officer: Sr. Vice President, Commercial 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Jeffrey Hessekiel officer: EVP and General Counsel 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
David Edward Johnson director 590 MADISON AVENUE, NEW YORK NY 10022
Dana Aftab officer: CSO/EVP Disc & Trans Research EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Amy C. Peterson officer: EVP Prod Dev & Med Aff & CMO C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Christopher J. Senner officer: EVP and CFO 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Bob Oliver director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Caligan Partners Lp director, other: See Remarks 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Jack L Wyszomierski director SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000
Alan M Garber director 3355 MILTON COURT, MOUNTAIN VIEW CA 94040
Carl B Feldbaum director C/O EXELIXIS INC, 170 HARBOR WAY, PO BOX 511, SOUTH SAN FRISCISCO CA 94083-0511
Peter Lamb officer: EVP, Discovery Research & CSO PO BOX 511, 170 HARBOR WAY, SOUTH SAN FRANCISCO CA 94083-0511
George Poste director 515 GALVESTON DR, REDWOOD CITY CA 94063
Lance Willsey director C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083